The results of this study showed that the ORR and CBR of the pyrotinib group were significantly higher than those of the trastuzumab group, and the PFS of the pyrotinib group was prolonged compared with that of the trastuzumab group, indicating that the combination of pyrotinib and capecitabine positive have better clinical outcomes and higher survival benefits for HER-2 positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.